Valtorcitabine

Drug Profile

Valtorcitabine

Alternative Names: Epcitabine; L-dC; LDC300; monoval-LdC; NM-147; NV-02C; Torcitabine; val-L-dC; Valtorcitabine dihydrochloride

Latest Information Update: 02 Oct 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Idenix Pharmaceuticals
  • Class Antivirals
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatitis B

Most Recent Events

  • 28 Sep 2007 Discontinued - Phase-II for Hepatitis B in USA (PO)
  • 18 May 2006 Phase-IIb clinical trials of valtorcitabine + telbivudine for Heptitis B in USA (PO)
  • 11 Jul 2005 Novartis has obtained the right to commercialise valtorcitabine in all areas of the world, Idenix has retained the right to co-promote or co-market in the US, UK, France, Germany, Spain and Italy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top